X0306 4 2013-08-27 0 0001311596 Regado Biosciences Inc RGDO 0001170144 QUAKER BIO VENTURES LP C/O CIRA CENTRE 2929 ARCH STREET PHILADELPHIA PA 19104 0 0 1 0 0001223034 QUAKER BIOVENTURES CAPITAL LP 435 DOVER PARK DRIVE BLDG 500 WAYNE PA 19087 0 0 1 0 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 399201 A 435129 D Common Stock, par value $0.001 per share 2013-08-27 4 C 0 273468 A 708597 D Common Stock, par value $0.001 per share 2013-08-27 4 C 0 465252 A 1173849 D Common Stock, par value $0.001 per share 2013-08-27 4 C 0 48362 A 1222211 D Common Stock, par value $0.001 per share 2013-08-27 4 P 0 71810 4.00 A 1294021 D Series B Preferred Stock 2013-08-27 4 C 0 6666667 0 D Common Stock, par value $0.001 per share 399201 0 D Series C Preferred Stock 2013-08-27 4 C 0 4566908 0 D Common Stock, par value $0.001 per share 273468 0 D Series D Preferred Stock 2013-08-27 4 C 0 7769715 0 D Common Stock, par value $0.001 per share 465252 0 D Series E Preferred Stock 2013-08-27 4 C 0 807652 0 D Common Stock, par value $0.001 per share 48362 0 D The reportable securities are directly held by Quaker BioVentures, L.P. (the "Reporting Person"). Quaker BioVentures Capital, L.P. ("Quaker Capital LP") is the general partner of the Quaker. Quaker BioVentures Capital, LLC ("Quaker Capital LLC") is the general partner of Quaker Capital LP and has voting and dispositive power over the shares held by the Reporting Person. Voting and investment determinations made by Quaker Capital LLC with respect to the shares held by the Reporting Person are made by an investment committee of Quaker Partners Management, L.P., which committee includes P. Sherrill Neff, a member of the board of the directors of the Company. The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. Quaker BioVentures, L.P. By: /s/ P. Sherrill Neff, the member of Quaker BioVentures Capital, LLC, the general partner of Quaker BioVentures Capital, L.P. 2013-08-29 Quaker BioVentures Capital, L.P. By: /s/ P. Sherrill Neff, member of Quaker BioVentures Capital, LLC, the GP of Quaker BioVentures Capital, L.P., the GP of Quaker BioVentures, L.P. 2013-08-29